Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

International Journal of Hematology

Volumn 78, Issue 1, 2003, Pages 56-61

  Oka, Yoshihiro ^a   Tsuboi, Akihiro ^a   Murakami, Masaki ^a   Hirai, Manabu ^b   Tominaga, Nobuhiko ^c   Nakajima, Hiroko ^a   Elisseeva, Olga A ^a   Masuda, Tomoki ^a   Nakano, Akiko ^a   Kawakami, Manabu ^a   Oji, Yusuke ^a   Ikegame, Kazuhiro ^a   Hosen, Naoki ^a   Udaka, Keiko ^d   Yasukawa, Masaki ^e   Ogawa, Hiroyasu ^a   Kawase, Ichiro ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c Suita Municipal Hospital   (Japan)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CTL; Immunotherapy; MDS; Wilms tumor gene; WT1

Indexed keywords

CYSTEINYLMETHIONYLTHREONYLTRYPTOPHYLASPARAGINYLGLUTAMINYLMETHIONYLASPARAGIN YLLEUCINE; DAUNORUBICIN; ENOCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PREDNISOLONE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADULT; ARTICLE; BLAST CELL; CANCER IMMUNOTHERAPY; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; HUMAN; LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION;

EID: 0042347518     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983241     Document Type: Article

References (37)

1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990;60:509-520.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990;343:774-778.
3. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene. Int Rev Cytol. 1998;181: 151-212.
4. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia. 1992;6:405-409.
5. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia. 1993;7:970-977.
6. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-3079.
7. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia. 1994;8:2138-2143.
8. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995;9:1060-1067.
9. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89: 1405-1412.
10. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13:393-399.
11. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol. 2001;73:177-187.
12. Shichishima T, Okamoto M, Ikeda K, et al. HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:22-28.
13. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194-204.
14. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene (WT1) predicts poor prognosis in breast cancer. J Clin Cancer Res. 2002;8:1167-1171.
15. Oji Y, Miyoshi S, Maeda H, et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer. 2002;100: 297-303.
16. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99-107.
17. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 2000;164:1873-1880.
18. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol. 2000;20:195-202.
19. Sugiyama H. Cancer immunotherapy targeting WT1 protein. Int J Hematol. 2002;76:127-132.
20. Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets. 2002;2:45-54.
21. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
22. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
23. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2002;8: 2626-2631.
24. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother. 2002;51:614-620.
25. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
26. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freunds' adjuvant for restricted high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
27. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002;99:3272-3279.
28. b transgenic mice. Int J Cancer. 2002; 100:565-570.
29. Mhawech P, Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit Rev Oncol Hematol. 2001;40: 229-238.
30. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96: 2012-2021.
31. Jaju RJ, Jones M, Boultwood J, et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q-syndrome. Genes Chromosomes Cancer. 2000;29:276-280.
32. van Lom K, Hagemeijer A, Smit E, Hahlen K, Groeneveld K, Lowenberg B. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia. 1995;9:1818-1821.
33. Miura I, Kobayashi Y, Takahashi N, Saito K, Miura AB. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br J Haematol. 2000;110: 876-879.
34. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132-2137.
35. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-2884.
36. Inoue K, Tamaki H, Ogawa H, et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood. 1998;91:2969-2976.
37. Tsuboi A, Oka Y, Ogawa H, et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res. 1999;23: 499-505.